These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

664 related items for PubMed ID: 29581249

  • 21. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for the Treatment of Anemia in Patients with CKD.
    Provenzano R, Besarab A, Sun CH, Diamond SA, Durham JH, Cangiano JL, Aiello JR, Novak JE, Lee T, Leong R, Roberts BK, Saikali KG, Hemmerich S, Szczech LA, Yu KP, Neff TB.
    Clin J Am Soc Nephrol; 2016 Jun 06; 11(6):982-991. PubMed ID: 27094610
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Mononuclear phagocytes orchestrate prolyl hydroxylase inhibition-mediated renoprotection in chronic tubulointerstitial nephritis.
    Schley G, Klanke B, Kalucka J, Schatz V, Daniel C, Mayer M, Goppelt-Struebe M, Herrmann M, Thorsteinsdottir M, Palsson R, Beneke A, Katschinski DM, Burzlaff N, Eckardt KU, Weidemann A, Jantsch J, Willam C.
    Kidney Int; 2019 Aug 06; 96(2):378-396. PubMed ID: 31146971
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. HIF-1 induced tiRNA-Lys-CTT-003 is protective against cisplatin induced ferroptosis of renal tubular cells in mouse AKI model.
    Li D, Xie X, Zhan Z, Li N, Yin N, Yang S, Liu J, Wang J, Li Z, Yi B, Zhang H, Zhang W.
    Biochim Biophys Acta Mol Basis Dis; 2024 Oct 06; 1870(7):167277. PubMed ID: 38871033
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury.
    Wei H, Gou W, Gao J, Ning H, Song Y, Li D, Qin Y, Hou W, Li Y.
    Eur J Med Chem; 2022 Feb 15; 230():114115. PubMed ID: 35033824
    [Abstract] [Full Text] [Related]

  • 29. Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.
    Mäkinen S, Sree S, Ala-Nisula T, Kultalahti H, Koivunen P, Koistinen HA.
    Diabetologia; 2024 Sep 15; 67(9):1943-1954. PubMed ID: 38814443
    [Abstract] [Full Text] [Related]

  • 30. Anti-anemia drug FG4592 retards the AKI-to-CKD transition by improving vascular regeneration and antioxidative capability.
    Wu M, Chen W, Miao M, Jin Q, Zhang S, Bai M, Fan J, Zhang Y, Zhang A, Jia Z, Huang S.
    Clin Sci (Lond); 2021 Jul 30; 135(14):1707-1726. PubMed ID: 34255035
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor Roxadustat (FG-4592) for Treatment of Anemia in Chronic Kidney Disease: A Placebo-Controlled Study of Pharmacokinetic and Pharmacodynamic Profiles in Hemodialysis Patients.
    Provenzano R, Tumlin J, Zabaneh R, Chou J, Hemmerich S, Neff TB, Yu KP.
    J Clin Pharmacol; 2020 Nov 30; 60(11):1432-1440. PubMed ID: 32603526
    [Abstract] [Full Text] [Related]

  • 33. Effects of orally active hypoxia inducible factor alpha prolyl hydroxylase inhibitor, FG4592 on renal fibrogenic potential in mouse unilateral ureteral obstruction model.
    Kabei K, Tateishi Y, Shiota M, Osada-Oka M, Nishide S, Uchida J, Nakatani T, Matsunaga S, Yamaguchi T, Tomita S, Miura K.
    J Pharmacol Sci; 2020 Mar 30; 142(3):93-100. PubMed ID: 31866051
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors: A Potential New Treatment for Anemia in Patients With CKD.
    Gupta N, Wish JB.
    Am J Kidney Dis; 2017 Jun 30; 69(6):815-826. PubMed ID: 28242135
    [Abstract] [Full Text] [Related]

  • 37. Roxadustat Attenuates Adverse Remodeling Following Myocardial Infarction in Mice.
    Zaruba MM, Staggl S, Ghadge SK, Maurer T, Gavranovic-Novakovic J, Jeyakumar V, Schönherr P, Wimmer A, Pölzl G, Bauer A, Messner M.
    Cells; 2024 Jun 21; 13(13):. PubMed ID: 38994928
    [Abstract] [Full Text] [Related]

  • 38. Roxadustat for Anemia in Patients with Kidney Disease Not Receiving Dialysis.
    Chen N, Hao C, Peng X, Lin H, Yin A, Hao L, Tao Y, Liang X, Liu Z, Xing C, Chen J, Luo L, Zuo L, Liao Y, Liu BC, Leong R, Wang C, Liu C, Neff T, Szczech L, Yu KP.
    N Engl J Med; 2019 Sep 12; 381(11):1001-1010. PubMed ID: 31340089
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 34.